Literature DB >> 16961672

Effects of antihypertensive drug treatments on fracture outcomes: a meta-analysis of observational studies.

M Wiens1, M Etminan, S S Gill, B Takkouche.   

Abstract

OBJECTIVE: To quantitatively pool findings from observational studies on the risk of fracture outcomes associated with exposure to five antihypertensive drug classes: angiotensin-converting enzyme (ACE) inhibitors, diuretics (in particular thiazide diuretics), beta-blockers, calcium-channel blockers and alpha-blockers.
DESIGN: Systematic review and meta-analysis. DATA SOURCES: Publications listed in the MEDLINE, EMBASE and LILACS databases, the ISI proceedings, and bibliographies of retrieved articles. Sources were searched from the earliest possible dates through December 2005. REVIEW
METHODS: We included case-control and cohort studies presenting relative risks and confidence intervals (CIs) for the association between exposure to antihypertensive agents and fracture outcomes. Data were extracted onto a standardized computer worksheet. Study quality was assessed using a 10-point questionnaire specific to case-control or cohort study design.
RESULTS: Fifty-four studies were identified. Pooled estimates were computed using the software HEpiMA. The pooled relative risk (RR) of any fracture with use of thiazide diuretics was 0.86 (95% CI 0.81-0.92) and 1.14 (95% CI 0.84-1.54) with use of nonthiazide diuretics. There was a statistically significant reduction of any fracture with use of beta-blockers, (RR 0.86, 95% CI 0.70-0.98). The one study with ACE inhibitor data showed protection (RR 0.81, 95% CI 0.73-0.89). No significant associations were found between fractures and exposure to alpha-blockers or calcium-channel blockers.
CONCLUSIONS: Thiazide diuretics and beta-blockers appear to lower the risk of fractures in older adults. However, these agents cannot be recommended as preventive therapies for fractures until data from randomized controlled trials have established their efficacy. Patients who use these inexpensive drugs as treatments for hypertension may also benefit from a reduction in fracture risk.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16961672     DOI: 10.1111/j.1365-2796.2006.01695.x

Source DB:  PubMed          Journal:  J Intern Med        ISSN: 0954-6820            Impact factor:   8.989


  51 in total

Review 1.  Evolving concepts in neurogenic osteoporosis.

Authors:  Weiping Qin; William A Bauman; Christopher P Cardozo
Journal:  Curr Osteoporos Rep       Date:  2010-12       Impact factor: 5.096

Review 2.  The Key Role of the Blood Supply to Bone.

Authors:  Massimo Marenzana; Timothy R Arnett
Journal:  Bone Res       Date:  2013-09-25       Impact factor: 13.567

Review 3.  Regulation of bone remodeling by the central and peripheral nervous system.

Authors:  Florent Elefteriou
Journal:  Arch Biochem Biophys       Date:  2008-03-23       Impact factor: 4.013

4.  Mice lacking beta-adrenergic receptors have increased bone mass but are not protected from deleterious skeletal effects of ovariectomy.

Authors:  M L Bouxsein; M J Devlin; V Glatt; H Dhillon; D D Pierroz; S L Ferrari
Journal:  Endocrinology       Date:  2008-09-18       Impact factor: 4.736

5.  The skeleton and the sympathetic nervous system: it's about time!

Authors:  Katherine J Motyl; Clifford J Rosen
Journal:  J Clin Endocrinol Metab       Date:  2012-11       Impact factor: 5.958

6.  The ageing endocrine system: Fracture risk after initiation of antihypertensive therapy.

Authors:  Lars Rejnmark
Journal:  Nat Rev Endocrinol       Date:  2013-02-05       Impact factor: 43.330

7.  Intensive blood pressure control, falls, and fractures in patients with type 2 diabetes: the ACCORD trial.

Authors:  Karen L Margolis; Lisa Palermo; Eric Vittinghoff; Gregory W Evans; Hal H Atkinson; Bruce P Hamilton; Robert G Josse; Patrick J O'Connor; Debra L Simmons; Margaret Tiktin; Ann V Schwartz
Journal:  J Gen Intern Med       Date:  2014-08-16       Impact factor: 5.128

8.  β-Adrenergic receptor antagonists and fracture risk: a meta-analysis of selectivity, gender, and site-specific effects.

Authors:  K A Toulis; K Hemming; S Stergianos; K Nirantharakumar; J P Bilezikian
Journal:  Osteoporos Int       Date:  2013-10-10       Impact factor: 4.507

9.  Health outcome priorities among competing cardiovascular, fall injury, and medication-related symptom outcomes.

Authors:  Mary E Tinetti; Gail J McAvay; Terri R Fried; Heather G Allore; Joanna C Salmon; Joanne M Foody; Luann Bianco; Sandra Ginter; Liana Fraenkel
Journal:  J Am Geriatr Soc       Date:  2008-07-24       Impact factor: 5.562

Review 10.  Long-term therapy in COPD: any evidence of adverse effect on bone?

Authors:  Arnulf Langhammer; Siri Forsmo; Unni Syversen
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2009-10-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.